Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letetresgene autoleucel in Multiple Myeloma
NCT01892293Phase 2Terminated
- Sponsor
- Adaptimmune Therapeutics
- Start
- Oct 2013
- Primary completion
- Dec 2014
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of letetresgene autoleucel in multiple myeloma (MM), sponsored by Adaptimmune Therapeutics. Started Oct 2013; status: terminated.
02
Drugs
letetresgene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01892293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01892293.